Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's product candidates [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from March 24, 2023, to May 14, 2025 [3]. - Allegations include that Biohaven overstated the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder [3]. - The lawsuit claims that the misleading statements are likely to have a significant negative impact on Biohaven's business and financial condition [3]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by the deadline of September 12, 2025 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Points - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit related to misleading statements made by the company during the class period from March 24, 2023, to May 14, 2025 [1] - Allegations include overstated regulatory prospects for the product candidate troriluzole and its efficacy for treating bipolar disorder, which may negatively impact Biohaven's business and financial condition [1] - Shareholders are encouraged to register for the class action by the deadline of September 12, 2025, to potentially become lead plaintiffs and receive updates on the case [2] Company Information - Biohaven Ltd. is facing allegations of issuing materially false and misleading statements regarding its product candidates, which could lead to significant financial repercussions [1] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to the company's alleged deceitful practices [3] Next Steps for Shareholders - Shareholders who purchased shares of Biohaven during the specified class period should register to participate in the class action, with no cost or obligation involved [2] - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]

Core Viewpoint - A class action has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Action - The class action alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the eventual revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Biohaven Ltd. due to allegations of misleading statements regarding the company's drug regulatory prospects and clinical efficacy, which have negatively impacted its stock price and investor confidence [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Biohaven between March 24, 2023, and May 14, 2025, to discuss their legal options [1][4]. - A federal securities class action has been filed against Biohaven, with a deadline of September 12, 2025, for investors to seek the role of lead plaintiff [4][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against Biohaven - The complaint alleges that Biohaven and its executives made false and misleading statements regarding the regulatory prospects of the drug troriluzole for treating spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder [6]. - The allegations suggest that the overstated claims about the drugs' prospects were likely to have a significant negative impact on Biohaven's business and financial condition [6]. Group 3: Stock Price Impact - Following a press release on May 14, 2025, regarding the extension of the PDUFA date for the troriluzole NDA, Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share on May 15, 2025 [7].

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and overstated the efficacy of BHV-7000 for bipolar disorder [2]. - It is alleged that the misleading statements were likely to have a significant negative impact on Biohaven's business and financial condition once revealed [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's product candidates and their regulatory prospects [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 24, 2023, to May 14, 2025 [3]. - Allegations include that Biohaven overstated the regulatory prospects of its product candidate, troriluzole, for treating SCA, and the efficacy of BHV-7000 for bipolar disorder [3]. - The complaint asserts that these misrepresentations are likely to have a significant negative impact on Biohaven's business and financial condition once revealed [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 12, 2025, to potentially be appointed as lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Group 1 - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit related to misleading statements made by the company during the class period from March 24, 2023, to May 14, 2025 [1] - Allegations include that Biohaven overstated the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder, which could negatively impact the company's business and financial condition [1] - Shareholders are encouraged to register for the class action by the deadline of September 12, 2025, to potentially be appointed as lead plaintiff and receive updates on the case [2] Group 2 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, aiming to ensure responsible business practices [3] - The firm seeks recovery for investors who suffered losses due to false or misleading statements that artificially inflated the company's stock [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2] Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 12, 2025 deadline [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that during the class period, Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder, which were overstated [4] - The lawsuit claims that the revelation of the true details would likely have a significant negative impact on Biohaven's business and financial condition, resulting in investor damages [4]

Core Viewpoint - The complaint against Biohaven alleges violations of federal securities laws due to misleading statements regarding the regulatory prospects of its drug troriluzole for spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder, which could significantly impact the company's financial condition [2] Group 1 - Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share following the announcement of an extended PDUFA date for the troriluzole NDA [3] - The FDA extended the PDUFA date for the troriluzole NDA by three months to allow for a full review of Biohaven's recent submissions [3] - An advisory committee meeting is planned by the FDA to discuss the application, although no date has been set [3] Group 2 - The lead plaintiff in the class action is the investor with the largest financial interest in the relief sought and is responsible for directing the litigation on behalf of the class [4] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4] Group 3 - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Biohaven's conduct to come forward, including whistleblowers and former employees [5]

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder, which were overstated [2]. - The complaint suggests that the revelation of these misstatements would likely have a significant negative impact on Biohaven's business and financial condition [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].